Previous 10 | Next 10 |
– Agreement provides immediate access to cash flow – – EPI Health leveraging accounts receivables from commercial product sales to bolster working capital needs – DURHAM, N.C., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” o...
– Paula Brown Stafford, President and Chief Executive Officer of Novan to participate in a live moderated panel discussion on Thursday, December 8th at 11:00 AM ET – DURHAM, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”...
Novan, Inc. (NOVN) Q3 2022 Earnings Conference Call November 14, 2022 08:30 ET Company Participants Paula Brown Stafford - Chairman, President, and Chief Executive Officer John Gay - Chief Financial Officer John Donofrio - Chief Operating Officer and President, E...
Novan ( NASDAQ: NOVN ) stock fell ~18% on Monday after Q3 revenue missed analysts estimates. Net loss marginally narrowed to -$6.03M, compared to -$6.48M in Q3 2021. Total revenue grew +594% Y/Y to ~$5.12M. Net product revenues were $4.6M, which represent...
Novan press release ( NASDAQ: NOVN ): Q3 GAAP EPS of -$0.25 beats by $0.14 . Revenue of $5.11M (+590.5% Y/Y) misses by $1.17M . As of September 30, 2022, Novan had a total cash and cash equivalents balance of $14.9 million. For further details see: No...
– Rhofade prescriptions increased 37% for third quarter year-to-date from prior year – – Continued progress toward submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeted around the end of 2022 – – Company to host...
Novan ( NASDAQ: NOVN ) is scheduled to announce Q3 earnings results on Monday, November 14th, before market open. The consensus EPS Estimate is -$0.40 (-17.6% Y/Y) and the consensus Revenue Estimate is $6.28M (+748.6% Y/Y). Over the last 1 year, NOVN has beaten EPS e...
DURHAM, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its third quarter 2022 financial results on Monday, November 14 th . Novan management will host a conference call and li...
DURHAM, N.C. and COPENHAGEN, Denmark, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), EPI Health, a Novan Company, and MC2 Therapeutics today announced positive data demonstrating the impact of PAD Technology™ in WY...
DURHAM, N.C. and COPENHAGEN, Denmark, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), EPI Health, a Novan Company, and MC2 Therapeutics today announced that data from a 17-question survey sponsored by the Company was publi...
News, Short Squeeze, Breakout and More Instantly...
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward...
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6...
– Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business transaction continues – – Continued progress ...